Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection
BackgroundClara cell 16 kDa protein (CC16) is a secretory protein primarily expressed in epithelial cells in the lungs. Previous studies show that CC16 exerts anti-inflammatory and immune-modulatory properties in both acute and chronic pulmonary diseases. However, despite the evidence of CC16’s high...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1037115/full |
| _version_ | 1811240577864302592 |
|---|---|
| author | Nathalie Rohmann Paula Stürmer Corinna Geisler Kristina Schlicht Katharina Hartmann Kathrin Türk Tim Hollstein Florian Tran Philip Rosenstiel Andre Franke Jan Heyckendorf Stefan Schreiber Dominik M. Schulte Dominik M. Schulte Matthias Laudes Matthias Laudes |
| author_facet | Nathalie Rohmann Paula Stürmer Corinna Geisler Kristina Schlicht Katharina Hartmann Kathrin Türk Tim Hollstein Florian Tran Philip Rosenstiel Andre Franke Jan Heyckendorf Stefan Schreiber Dominik M. Schulte Dominik M. Schulte Matthias Laudes Matthias Laudes |
| author_sort | Nathalie Rohmann |
| collection | DOAJ |
| description | BackgroundClara cell 16 kDa protein (CC16) is a secretory protein primarily expressed in epithelial cells in the lungs. Previous studies show that CC16 exerts anti-inflammatory and immune-modulatory properties in both acute and chronic pulmonary diseases. However, despite the evidence of CC16’s high biomarker potential, evaluation of its role in infectious diseases is yet very limited.MethodsSerum CC16 concentrations were measured by ELISA and assessed in two different types of severe infections. Using a case-control study design, patients treated for either severe SARS-CoV-2 or severe non-pulmonary sepsis infection were compared to age- and sex-matched healthy human subjects.ResultsSerum CC16 was significantly increased in both types of infection (SARS-CoV-2: 96.22 ± 129.01 ng/ml vs. healthy controls: 14.05 ± 7.48 ng/ml, p = 0.022; sepsis: 35.37 ± 28.10 ng/ml vs. healthy controls: 15.25 ± 7.51 ng/ml, p = 0.032) but there were no distinct differences between infections with and without pulmonary focus (p = 0.089). Furthermore, CC16 serum levels were positively correlated to disease duration and inversely to the platelet count in severe SARS-CoV-2 infection.ConclusionsIncreased CC16 serum levels in both SARS-CoV-2 and sepsis reinforce the high potential as a biomarker for epithelial cell damage and bronchoalveolar−blood barrier leakage in pulmonary as well as non-pulmonary infectious diseases. |
| first_indexed | 2024-04-12T13:22:42Z |
| format | Article |
| id | doaj.art-2e88b2cee9014096bb197c9af87755da |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T13:22:42Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2e88b2cee9014096bb197c9af87755da2022-12-22T03:31:25ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.10371151037115Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infectionNathalie Rohmann0Paula Stürmer1Corinna Geisler2Kristina Schlicht3Katharina Hartmann4Kathrin Türk5Tim Hollstein6Florian Tran7Philip Rosenstiel8Andre Franke9Jan Heyckendorf10Stefan Schreiber11Dominik M. Schulte12Dominik M. Schulte13Matthias Laudes14Matthias Laudes15Institute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel, GermanyInstitute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel, GermanyInstitute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel, GermanyInstitute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel, GermanyInstitute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel, GermanyInstitute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel, GermanyDivision of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, GermanyInstitute of Clinical Molecular Biology, Kiel University, Kiel, GermanyInstitute of Clinical Molecular Biology, Kiel University, Kiel, GermanyInstitute of Clinical Molecular Biology, Kiel University, Kiel, GermanyDivision of Pneumology, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, GermanyInstitute of Clinical Molecular Biology, Kiel University, Kiel, GermanyInstitute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel, GermanyDivision of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, GermanyInstitute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel, GermanyDivision of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, GermanyBackgroundClara cell 16 kDa protein (CC16) is a secretory protein primarily expressed in epithelial cells in the lungs. Previous studies show that CC16 exerts anti-inflammatory and immune-modulatory properties in both acute and chronic pulmonary diseases. However, despite the evidence of CC16’s high biomarker potential, evaluation of its role in infectious diseases is yet very limited.MethodsSerum CC16 concentrations were measured by ELISA and assessed in two different types of severe infections. Using a case-control study design, patients treated for either severe SARS-CoV-2 or severe non-pulmonary sepsis infection were compared to age- and sex-matched healthy human subjects.ResultsSerum CC16 was significantly increased in both types of infection (SARS-CoV-2: 96.22 ± 129.01 ng/ml vs. healthy controls: 14.05 ± 7.48 ng/ml, p = 0.022; sepsis: 35.37 ± 28.10 ng/ml vs. healthy controls: 15.25 ± 7.51 ng/ml, p = 0.032) but there were no distinct differences between infections with and without pulmonary focus (p = 0.089). Furthermore, CC16 serum levels were positively correlated to disease duration and inversely to the platelet count in severe SARS-CoV-2 infection.ConclusionsIncreased CC16 serum levels in both SARS-CoV-2 and sepsis reinforce the high potential as a biomarker for epithelial cell damage and bronchoalveolar−blood barrier leakage in pulmonary as well as non-pulmonary infectious diseases.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1037115/fullCC16SARS-CoV-2sepsisepithelial cell damagebiomarker |
| spellingShingle | Nathalie Rohmann Paula Stürmer Corinna Geisler Kristina Schlicht Katharina Hartmann Kathrin Türk Tim Hollstein Florian Tran Philip Rosenstiel Andre Franke Jan Heyckendorf Stefan Schreiber Dominik M. Schulte Dominik M. Schulte Matthias Laudes Matthias Laudes Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection Frontiers in Immunology CC16 SARS-CoV-2 sepsis epithelial cell damage biomarker |
| title | Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection |
| title_full | Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection |
| title_fullStr | Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection |
| title_full_unstemmed | Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection |
| title_short | Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection |
| title_sort | brief research report serum clara cell 16 kda protein levels are increased in patients hospitalized for severe sars cov 2 or sepsis infection |
| topic | CC16 SARS-CoV-2 sepsis epithelial cell damage biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1037115/full |
| work_keys_str_mv | AT nathalierohmann briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT paulasturmer briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT corinnageisler briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT kristinaschlicht briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT katharinahartmann briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT kathrinturk briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT timhollstein briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT floriantran briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT philiprosenstiel briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT andrefranke briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT janheyckendorf briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT stefanschreiber briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT dominikmschulte briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT dominikmschulte briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT matthiaslaudes briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection AT matthiaslaudes briefresearchreportserumclaracell16kdaproteinlevelsareincreasedinpatientshospitalizedforseveresarscov2orsepsisinfection |